GSK 1437173A

Drug Profile

GSK 1437173A

Alternative Names: GSK1437173A; Herpes zoster vaccine candidate (Hz/su) - GlaxoSmithKline; HZ/su; QS-21 containing herpes zoster vaccine - GlaxoSmithKline/Agenus; Shingrix; Varicella zoster vaccine - GlaxoSmithKline; Varicella zoster virus vaccine - GlaxoSmithKline; VZV vaccine - GlaxoSmithKline/Agenus

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Japan Vaccine
  • Class Subunit vaccines; Varicella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Herpes zoster

Most Recent Events

  • 18 Apr 2017 Preregistration for Herpes zoster (Prevention, In adults, In the elderly) in Japan (IM)
  • 01 Feb 2017 GlaxoSmithKline completes a phase III trial in Herpes zoster (Prevention) in Australia, Belgium, Bulgarioa, Canada, Czech Republic, Estonia, Finland, France, Germany, Greece, Hong Kong, Israel, Italy, Japan, South Korea, Malaysia, Netherlands, New Zealand, Panama, Poland, Romania, Russia, South Africa, Spain, Taiwan, Turkey, United Kingdom and USA (IM) (NCT01610414)
  • 01 Jan 2017 GlaxoSmithKline initiates enrolment in a phase III trial for Herpes zoster (In adults, In the elderly, Prevention) in USA (NCT02979639)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top